Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2787.

https://doi.org/10.1182/blood-2023-186947

Published: 2023

Journal Articles

Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3 Mutation

Eric S. Winer, Amit Verma, Stefanie Groepper, Katharina S. S. Götze, Yasmin Abaza, Christoph Schliemann, Gaurav S Choudhary, Wanying Zhao, Cole Gallagher, Reinhard von Roemeling, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 2924.

https://doi.org/10.1182/blood-2023-190007

Published: 2023

Journal Articles

Trial in Progress: A Phase 1b Single-Arm, Open-Label Study of Emavusertib (CA-4948) in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease

Adolfo De La Fuente Burguera, Claudio Cerchione, Sebastian Scholl, Jan Moritz Middeke, Gaurav S Choudhary, Reinhard von Roemeling, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 5975.

https://doi.org/10.1182/blood-2023-190125

Published: 2023

Journal Articles

Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML

Bianca L Rivera, Samarpana Chakraborty, Yang Shi, Hui Zhang, Gaurav S Choudhary, Shanisha Gordon, Kith Pradhan, Bowen Fu, Isidora Tosic, Rongbao Zhao, Mendel Goldfinger, Ioannis Mantzaris, Milagros Carbajal, Nandini Ramachandra, Marina Konopleva, David Frank, Yogenthiran Saunthararajah, Amit Verma, Aditi Shastri

Blood (2022) 140 (Supplement 1): 6892–6893.

https://doi.org/10.1182/blood-2022-163255

Published: 2022

Journal Articles

Preclinical Activity of the Clinical Stage Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Splicing Mutant Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Leya Y Schwartz, Gaurav S Choudhary, Nandini Ramachandra, Srabani Sahu, Shanisha Gordon, Bruce Ruggeri, Diane Heiser, Peggy Scherle, Daniel Starczynowski, Amit Verma

Blood (2021) 138 (Supplement 1): 2597.

https://doi.org/10.1182/blood-2021-148494

Published: 2021

Journal Articles

A Transgenic Murine Model Expressing Hyperactive STAT3 Recapitulates the Features of MDS/AML

Bianca L Rivera, Shanisha Gordon, Srinivas Aluri, Yang Shi, Samarpana Chakraborty, Gaurav S Choudhary, Lauren C Shapiro, Kith Pradhan, David A. Frank, Sergei B. Koralov, Amit Verma, Aditi Shastri

Blood (2021) 138 (Supplement 1): 3308.

https://doi.org/10.1182/blood-2021-151691

Published: 2021

Journal Articles

Selective Targeting of Splicing Factor Mutant Hematopoietic Stem and Progenitor Cells Via STAT3 Inhibition

Kathryn S Potts, Rosannah C. Cameron, Noura Ghazale, Varun Gupta, Juan Martin Barajas, LaShanale Wallace, Ana Leal-Cervantes, Srinivas Aluri, Kith Pradhan, Mia McKinstry, Xiaoying Bai, Gaurav S Choudhary, Aditi Shastri, Amit Verma, Esther A. Obeng, Teresa V. Bowman

Blood (2021) 138 (Supplement 1): 1509.

https://doi.org/10.1182/blood-2021-151338

Published: 2021

Journal Articles

SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML

Blood (2019) 134 (Supplement_1): 4224.

https://doi.org/10.1182/blood-2019-124458

Published: 2019

Journal Articles

Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS

Srinivas Aluri, Kimo Bachiashvili, MD, Anjali Budhathoki, MD, Tushar D Bhagat, PhD, Gaurav S Choudhary, PhD, Shanisha Gordon, Nandini Ramachandra, Kith Pradhan, PhD, Shahina Maqbool, Aditi Shastri, MD, Jung Im Huh, Sunjin Hwang, Kim Seong-Jin, PhD, Hui Zhang, Britta Will, PhD, Amittha Wickrema, PhD, Ulrich G. Steidl, MD PhD, Amit Verma, MBBS

Blood (2019) 134 (Supplement_1): 2990.

https://doi.org/10.1182/blood-2019-127561

Published: 2019

Journal Articles

High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster

Blood (2019) 134 (Supplement_1): 3720.

https://doi.org/10.1182/blood-2019-129276

Published: 2019

Journal Articles

North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies

Blood (2018) 132 (14): 1507–1518.

https://doi.org/10.1182/blood-2018-01-824607

Published: 2018

Includes: Supplemental data

NARROW

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3 Mutation

Trial in Progress: A Phase 1b Single-Arm, Open-Label Study of Emavusertib (CA-4948) in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease

Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML

Preclinical Activity of the Clinical Stage Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Splicing Mutant Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

A Transgenic Murine Model Expressing Hyperactive STAT3 Recapitulates the Features of MDS/AML

Selective Targeting of Splicing Factor Mutant Hematopoietic Stem and Progenitor Cells Via STAT3 Inhibition

SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML

Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS

High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster

North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only